JP2011144201A5 - - Google Patents

Download PDF

Info

Publication number
JP2011144201A5
JP2011144201A5 JP2011093677A JP2011093677A JP2011144201A5 JP 2011144201 A5 JP2011144201 A5 JP 2011144201A5 JP 2011093677 A JP2011093677 A JP 2011093677A JP 2011093677 A JP2011093677 A JP 2011093677A JP 2011144201 A5 JP2011144201 A5 JP 2011144201A5
Authority
JP
Japan
Prior art keywords
medicament
use according
respiratory
asthma
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011093677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011144201A (ja
Filing date
Publication date
Priority claimed from GBGB0405634.7A external-priority patent/GB0405634D0/en
Application filed filed Critical
Publication of JP2011144201A publication Critical patent/JP2011144201A/ja
Publication of JP2011144201A5 publication Critical patent/JP2011144201A5/ja
Pending legal-status Critical Current

Links

JP2011093677A 2004-03-12 2011-04-20 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β Pending JP2011144201A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases
GB0405634.7 2004-03-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007502414A Division JP4807526B2 (ja) 2004-03-12 2005-03-07 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β

Publications (2)

Publication Number Publication Date
JP2011144201A JP2011144201A (ja) 2011-07-28
JP2011144201A5 true JP2011144201A5 (enExample) 2012-10-18

Family

ID=32117582

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007502414A Expired - Fee Related JP4807526B2 (ja) 2004-03-12 2005-03-07 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β
JP2011093677A Pending JP2011144201A (ja) 2004-03-12 2011-04-20 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007502414A Expired - Fee Related JP4807526B2 (ja) 2004-03-12 2005-03-07 呼吸器疾患の抗ウイルス療法のためのインターフェロン−β

Country Status (12)

Country Link
US (3) US7569216B2 (enExample)
EP (2) EP2206512A3 (enExample)
JP (2) JP4807526B2 (enExample)
AT (1) ATE466591T1 (enExample)
CA (2) CA2787978A1 (enExample)
DE (1) DE602005021078D1 (enExample)
DK (1) DK1734987T3 (enExample)
ES (1) ES2343732T3 (enExample)
GB (1) GB0405634D0 (enExample)
PL (1) PL1734987T3 (enExample)
PT (1) PT1734987E (enExample)
WO (1) WO2005087253A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
JP5172679B2 (ja) * 2005-09-09 2013-03-27 インペリアル イノベーションズ リミテッド 呼吸器疾患の治療のためのインターフェロン−λ療法
CA2622987C (en) * 2005-09-20 2018-02-27 New York University Method of treating pulmonary disease with interferons
DE102006022877B4 (de) 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
GB0713402D0 (en) * 2007-07-11 2007-08-22 Cardiff & Vale Nhs Trust A method of diagnosing a condition using a neural network
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
JP2012512883A (ja) * 2008-12-19 2012-06-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ウイルス感染の治療における上皮成長因子阻害剤の使用
CA2782512A1 (en) * 2009-12-02 2011-06-09 Neetour Medical Ltd. Hemodynamics-based monitoring and evaluation of a respiratory condition
US9421243B2 (en) * 2010-03-12 2016-08-23 Synairgen Research Limited Therapy for influenza like illness
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
CN109293782A (zh) 2014-01-08 2019-02-01 德益阳光生物技术(北京)有限责任公司 融合多肽及使用方法
CN111148509A (zh) * 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
IL275360B2 (en) 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
EP3923975A4 (en) * 2019-02-13 2023-04-19 University of Florida Research Foundation, Inc. TARGETING A LUNG-RESIDENT TNFR2 + CDC2 (R2D2) SUBPULATION FOR THE TREATMENT OF ASTHMA
NZ783377A (en) 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2
EP4181944A1 (en) 2020-07-20 2023-05-24 Synairgen Research Limited Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients
GB202014114D0 (en) * 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
EP4240396B1 (en) * 2020-11-04 2025-01-01 Ethris GmbH Ifn-lambda mrna for treating viral infections
WO2022154542A1 (ko) * 2021-01-13 2022-07-21 에이비온 주식회사 잠재적인 호흡기바이러스 감염 개체에 인터페론-베타를 투여하는 것을 포함하는 호흡기바이러스에 대한 예방적 투여 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
WO2002036628A2 (en) 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
WO2003066002A2 (en) 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
CA2503305A1 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
JP4808157B2 (ja) 2003-08-07 2011-11-02 ザイモジェネティクス リミテッド ライアビリティ カンパニー Il−28およびil−29の均一な調製物
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
AU2005231476B2 (en) 2004-04-02 2011-09-01 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection

Similar Documents

Publication Publication Date Title
He et al. Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy
Newman Delivering drugs to the lungs: The history of repurposing in the treatment of respiratory diseases
Virk et al. Mast cells and their activation in lung disease
JP2012503668A5 (enExample)
JP2013224331A5 (enExample)
CY1121090T1 (el) Εισπνευσιμα σωματιδια που περιλαμβανουν τιοτροπιο
JP2015517983A5 (enExample)
EA201201392A1 (ru) Кнопочное устройство мундштука ингалятора сухого порошка
IN2014DN08672A (enExample)
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
EP2682108A3 (en) Dry Powder Inhalers Comprising a Carrier Other Than Lactose and a Ternary Component
EA201201397A1 (ru) Ингалятор, содержащий расслаиваемую блистерную упаковку
JP2015511625A5 (enExample)
EP2682097A3 (en) Dry Powder Inhalers Comprising A Carrier Other Than Lactose
CA2558212A1 (en) Interferon-beta for anti-virus therapy for respiratory diseases
EA201201395A1 (ru) Кнопочное устройство мундштука ингалятора сухого порошка
JP2007520507A5 (enExample)
EA201201393A1 (ru) Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка
JP2014520874A5 (enExample)
EA201201391A1 (ru) Ингалятор
UA115989C2 (uk) Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії
ME02610B (me) Aklidinijum za upotrebu u poboljšanju kvaliteta sna kod respiratornih pacijenata
EA201201389A1 (ru) Ингалятор, создающий турбулентность
JP2009514794A5 (enExample)
EA201201394A1 (ru) Ингалятор для доставки лекарственного средства в виде сухого порошка